Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan Downgrades Cyteir Therapeutics to Neutral

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

byBenzinga Newsdesk

January 20, 2023

1 minute read

JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.

What’s Going On With ContextLogic (WISH) Stock?

By Adam Eckert

September 26, 9:25 AM

ContextLogic Inc (NASDAQ: WISH) shares are trading lower Tuesday after rallying more than 12% on Monday.

WISH

SPX, SPY, QQQ: Why These Options Market Data Won’t Cheer You This Week

By Bhavik Nair

March 28, 5:29 AM

U.S. markets closed mixed on Monday as fears surrounding the banking crisis calmed following the takeover news regarding…

QQQ

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Avi Kapoor

April 9, 1:12 PM

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free

ACB

Morgan Stanley Maintains Overweight on Rocket Lab USA, Lowers Price Target to $12

By Benzinga Newsdesk

August 16, 7:54 AM

Morgan Stanley analyst Kristine Liwag maintains Rocket Lab USA (NASDAQ:RKLB) with a Overweight and lowers the price target from $16 to $12.

RKLB

JP Morgan Downgrades Cyteir Therapeutics to Neutral

Related Posts

What’s Going On With ContextLogic (WISH) Stock?

SPX, SPY, QQQ: Why These Options Market Data Won’t Cheer You This Week

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

Morgan Stanley Maintains Overweight on Rocket Lab USA, Lowers Price Target to $12